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matched and analyzed to see if there any trend and relation between the num-
ber of drugs added in the NHF and the percentage of deaths listed for each dis-
ease. Results: The NHF has drugs for every disease evaluated. In the period 
analyzed, the number of drugs for DM has increased from 18 to 24. In the case of 
IHD, the number has also grown from 20 to 32. For CD there has been also an addition 
from 10 to 13. The drugs for ALD is the same in each year (only one drug). At last, 
for COPD the number has change from 35 to 36 drugs. Comparing with the number 
of deaths, the IHD is the disease with the biggest increased of deaths (22%), then 
the DM with 12%, COPD 11%, ALD 4%, and CD 3%. ConClusions: Although there 
have been added new drugs prescribed for the diseases that caused the deaths of 
most population in the NHF, this quantity is not comparable with the growing of 
deaths observed in each disease.
PCV98
SoCioeConomiC FaCtorS and PreSCribed mediCineS exPenditureS 
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hyPerliPidemia PatientS With and Without treatment
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objeCtives: As reported by the Centers for Disease Control and Prevention (CDC) 
more than half of adults with high blood cholesterol level did not receive any treat-
ment. Untreated high blood cholesterol can lead to coronary heart diseases. The 
primary objective of this study is to describe and contrast the socioeconomic factors 
between treated and untreated patients with hyperlipidemia. Secondary objective is 
to compare prescribed medicines expenditures between the two groups. Methods: 
This study conducted cross-sectional secondary data analyses using 2012 Medical 
Expenditures Panel Survey (MEPS). Study subjects consisted of US civilian, non-
institutionalized adults diagnosed with high blood cholesterol. Series of statistical 
comparisons on socioeconomic factors, and prescribed medicines expenditures and 
utilizations between hyperlipidemia patients with any FDA-approved lipid lowering 
agent and hyperlipidemia patients without lipid lowering agents. The Andersen 
Behavioral Model was applied to define the socioeconomic factors. SAS 9.3 statistical 
software was used for all analyses including sample weights and standard errors 
adjustments. Results: Approximately 19 million patients had high blood choles-
terol related events in 2012. The average age of treatment group was older than the 
average age of no-treatment group, 64 and 62 years old respectively, (p< 0.001). 95% 
of hyperlipidemia patients with high income had treatment, on the contrary, 93% 
of hyperlipidemia patients with near poor income had treatment. The average total 
prescription expenditures for patients with treatment was higher than patients 
without treatment, $3032 and $2509 respectively, (p< 0.001). ConClusions: The 
study findings showed substantial number of hyperlipidemia patients without 
treatment. Also there were some socioeconomic differences between treatment 
group and no-treatment group. Further research is recommended to understand 
the complex role of socioeconomic factors in hyperlipidemia therapy to make more 
effective policies and programs designed to improve treatment for one of the major 
chronic conditions in the United States.
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objeCtives: To analyze the use of statins in 90 days after hemodialysis among the 
prior-users. Methods: This retrospective cohort study used the 1997-2008 National 
Health Insurance Research Data to analyze the use of statins among prior users 
aged 20 years or older after they started maintenance hemodialysis. These prior 
users were prescribed with statins at least once in 180 days prior to hemodialysis. 
Discontinuation of statin prescription was defined when there was no prescrip-
tion records in the following 90 days, and the date of discontinuation was coded 
as the last date of prescription plus medication period. We used Cox proportional 
hazard model to examine the potential factors attributable to the discontinuation 
of statin prescription. We also analyze the pattern of re-use of statins after one 
year. Results: Among 8982 statin users, 2079 patients continued to use statins 
after hemodialysis. In 90 days after hemodialysis, the average medication days 
among the continued users was 65.8 days. Among the discontinued users, 65% 
stopped using statins in the 90 days before hemodialysis; 8.7% of them started 
using statins in the first 6 months and 19% started in the first year again. Analysis 
of the Cox proportional hazard model showed that being male(HR 1.10, 95% CI 1.05, 
1.15) and no statin prescription in 90 days before hemodialysis(HR 1.78ï¿½, 95% 
CI 1.68, 1.87) were attributable to the discontinuation of statins in 90 days after 
hemodialysis; those with coronary heart disease(HR 0.93ï¿½, 95% CI 0.89, 0.98) and 
peripheral vascular disease(HR 0.87ï¿½, 95% CI 0.79, 0.96) tended to continue using 
statins. ConClusions: Most statin users stopped using statins after hemodialysis. 
In fact, most of them stopped using statins in the 90 days before hemodialysis. 
Subjects who were female and with medical history of cardiovascular diseases 
or peripheral vascular disease were more likely to continue using of statins after 
hemodialysis.
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objeCtives: Cardiovascular diseases (CVD) are the major health problem in con-
temporary world, particularly in developing countries. The impact of the costs 
of Agents acting on RAS to the healthcare budgets is relatively high. It is impor-
tant to establish the use of cheaper generic and to reduce the healthcare costs. 
The aim of our study was to identify and analyze changes in the usage of these 
up and significant reduction on medications consumption. Patients who increased 
BMI during the wait list presented lower rates of comorbidities resolution compared 
to patients who maintained or reduced their BMI in the wait list. Based on the out-
comes presented, bariatric surgery is a procedure that can help the Brazilian health 
system to treat obesity and its co-morbidities
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objeCtives: The efficacy of warfarin for reducing stroke risk is influenced by its 
time-in-therapeutic range (TTR, i.e. time patients spend having an international 
normalized prothrombin time ratio, INR= 2-3). This study evaluated warfarin TTRs 
among nonvalvular atrial fibrillation (NVAF) patients treated in an integrated 
healthcare delivery system (IDHS) setting. Methods: Patients with NVAF, war-
farin therapy, and INR measurements were identified from an electronic medical 
record database (1/1/2004-8/31/2013). NVAF patients were required to have ≥ 6 INR 
test values to ensure chronic warfarin therapy. Warfarin TTRs were determined by 
the modified Rosendaal method. INR values collected during hospitalization stays 
were not included in the TTR calculation, since they may not be indicative of poor 
INR control. Patient characteristics during a 12-month follow-up period after the 
first INR test were evaluated. Results: Among the NVAF study population, greater 
than half (54%, n= 1,595) had a low TTR (< 60%) and 46% (n= 1,356) had a high TTR 
(≥ 60%). Mean ages of patients with low and high TTR were 71.1 and 72.2 years, 
respectively. Charlson Comorbidity Index (2.9 vs. 2.3, p< 0.001) and CHADS2 (2.2 
vs. 2.0, p< 0.001) scores were higher for NVAF patients with low TTR vs. high TTR. 
Among NVAF patients with low TTR, 79% had a warfarin TTR < 55% and 21% had a 
TTR of 55-60% during the follow-up period. Among NVAF patients with high TTR, 
24%, 41%, and 35% had warfarin TTRs of 60-64%, of 65-74%, and ≥ 75%, respectively 
during the follow-up period. Among NVAF patients with low and high TTR, 45% 
and 73% of them spent time in the warfarin therapeutic range (INR between 2-3), 
respectively. ConClusions: Based on a conservative approach to evaluate the 
warfarin TTR, our results indicate that it still remains very challenging in a con-
temporary real-world setting to achieve consistently good levels for the majority 
of our NVAF patients.
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objeCtives: A key goal for managed care organizations is to improve patient 
health outcomes and reduce costs. One strategy involves increasing medication 
adherence among patients with chronic diseases. The Kentucky Department for 
Medicaid Services contracted with three managed care organizations in November 
2011 to transition the state’s traditional fee-for-service Medicaid patients into 
capitated managed care. The purpose of this study is to determine differences in 
medication adherence before and after the switch from fee-for-service to managed 
care for Medicaid patients in Kentucky with essential hypertension between 2010 
and 2012. Methods: The retrospective cohort study sample will be drawn from 
a database of Kentucky Medicaid patient (age 18-64) medical and prescription 
claims between 2010 and 2012. The University of Kentucky Internal Review Board 
approved the study. The study will include descriptive statistics of the medica-
tion possession ratio (MPR) and control variables including patient demographics, 
type of antihypertensive, and comorbidities. Bivariate analyses will measure the 
effect of each variable on the change in MPR as a result of the switch. Multivariate 
analysis will be a difference-in-difference regression model, measuring the pre and 
post differences in MPR due to the introduction of managed care. Results: Initial 
data collected indicate that average MPR decreased by about 13 percentage points, 
regardless of medication class, after Medicaid managed care in Kentucky took 
effect, with other factors held constant. A 13-percentage point decrease in MPR 
corresponds to about 45 fewer days of medication possession. ConClusions: 
Results are preliminary, but indicate a need to address the efficacy of Medicaid 
managed care on adherence to antihypertensives in Kentucky. Additional studies 
should be conducted with data from 2013 to ensure confounding due to transi-
tional issues is eliminated. Future studies will examine the effect of Medicaid 
managed care on adherence in hyperlipidemia, diabetes, asthma, and mental 
health disorders.
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PubliC health SyStem CoVering theSe needS?
Lemus F., Rivas R.
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objeCtives: The aim of this work is to demonstrate if the National Health 
Formulary (NHF) has included drugs related to the principal causes of death in the 
last 5 years (Diabetes Mellitus (DM), Ischemic Heart Diseases (IHD), Cerebrovascular 
Diseases (CD), Alcoholic Liver Diseases (ALD) and Chronic Obstructive Pulmonary 
Disease (COPD)), and if the number of the drugs added each year is in accordance 
with the increase number of deaths per disease. Methods: A search in the National 
Institute of Statistics and Geography and the National System of Information on 
Health was done, from 2009 to 2013, related to the 5 principal causes of death in 
Mexico. Then, there were counted and analyzed the number of drugs prescribed 
for each disease studied in the last 5 NHF editions. Finally, all data obtained was 
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estimated from 2006-2012 for all branded and generic monotherapy formulations 
of lisinopril, hydrochlorothiazide, metformin, and levothyroxine. Claims were con-
sidered GDDP-filled if the following criteria were met: the only recorded price paid 
was patient out-of-pocket, and the quantity dispensed and out-of-pocket price-
paid matched published GDDP pharmacy lists, including Walmart, Walgreens, CVS, 
RiteAid, and Kroger. Results: In 2006, the percentage of GDDP-filled prescriptions 
was low: 8.1% (N= 4,472,797) of hydrochlorothiazide, 4.0% (N= 3,880,992) of levo-
thyroxine, 0.01% (N= 4,008) of metformin, and 0.0% of lisinopril. This increased in 
2008, to 2.4% (N= 1,676,928) for metformin, 8.0% (N= 7,107,840) for lisinopril, 16.8% 
(N= 9,024,532) for hydrochlorothiazide, and 18.9% (N= 13,035,972) for levothyroxine. 
In 2009, all medications had a GDDP-filled rate around 20% or greater. The high-
est percentages were seen in 2010: 22.5% (N= 12,033,009) of hydrochlorothiazide, 
25.1% (N= 27,033,234) of levothyroxine, 25.5% (N= 17,593,051) of metformin, and 
29.6% (N= 30,115,329) of lisinopril. By 2012 this decreased, and 19.6% (N= 9,715,614) 
of hydrochlorothiazide, 20.3% (N= 20,813,050) of lisinopril, 22.1% (N= 21,425,226) of 
levothyroxine, and 23.2% (N= 17,842,540) of metformin prescriptions were GDDP-
filled. ConClusions: By 2012, approximately 1 in 5 prescriptions for lisinopril, 
hydrochlorothiazide, metformin, and levothyroxine were filled using a GDDP. As 
they are cash-only, these prescriptions may not be processed via a pharmacy benefit 
manager, and therefore may be missing from insurance claims data.
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objeCtives: ACE inhibitors and ARBs are the cornerstone of therapy for patients 
with hypertension and type 2 diabetes. However, they have been shown to be under-
utilized in elderly patients at high risk for complications. The objectives of this 
study are to 1) assess earlier use of ACEIs/ARBs after incident diabetes diagnosis by 
race/ethnicity groups, and 2) assess whether the use of ACEIs/ARBs improves over 
time after diabetes diagnosis by race/ethnicity group. Methods: We identified fee-
for-service Medicare beneficiaries over the age of 65 with hypertension and newly 
diagnosed T2DM using data from CMS. Treatment use, baseline demographics, and 
other covariates were measured during the 12-month baseline period and the index 
date. Standardized differences were used to assess ACEI/ARB use and a marginal 
effects model with GEE was applied to investigate race/ethnicity differences in 
use rates. Results: 55.5% of 135,923 patients received ACEI/ARB therapy within 3 
months post-diabetes diagnosis (65.2% ACEIs, 38.5% ARBs). ACEI/ARB users within 3 
months after a diabetes diagnosis were younger and had fewer comorbidities, except 
for hyperlipidemia. Compared to non-users, ACEIs/ARBs users had more medica-
tion use. Among the racial/ethnic subgroups, Asians and Hispanics had the highest 
rate of use (59%), followed by Other (56%), White (55%), and Black (53%). Asians and 
Hispanics had 4% and 6% higher RR for use and Blacks had a 2% lower RR compared 
to Whites. Overall, rates of use over time decreased by 1% to 2%, except for a mild 
increase among Blacks (1% to 2%). However, subgroup analyses indicated that the 
decrease could be attributed to patients receiving ACEI/ARB therapy prior to diabetes 
diagnosis. Untreated patients showed an increase in use over time. ConClusions: 
Overall, ACEIs/ARBs are underutilized based on current treatment guidelines and 
use varies significantly across races/ethnicities. Future studies are needed to assess 
reasons for underuse of ACEIs/ARBs to promote better health outcomes.
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objeCtives: The prevalence of statin use in older adults with new onset diabetes 
(T2DM), frequently presenting with co-morbidities and susceptible to poor out-
comes, has not been well characterized. The objective of this study was to exam-
ine and characterize the prevalence of statin use among Medicare patients newly 
diagnosed with diabetes, and to assess statins use gaps by age, gender, and race/
ethnicity as well as those with and without underlying cardiovascular disease 
(CVD). Methods: This was a retrospective cohort study using pharmacy and 
medical claims from CMS. Enrollees with a new T2DM diagnosis (index date) in 
2008, aged 65 years or older, continuously enrolled in Medicare Part A, B, and D, and 
who survived at least 90 days after the index date were included. The prevalence 
of statin use within 90 days of index date across age, gender, race/ethnicity, and 
baseline CVD status was assessed. Multivariable logistic regression was applied to 
investigate the effects of the independent variables. Results: An average statin 
usage rate of 46.3% was found in the 168,800 eligible patients included in the study. 
66,525 patients in the cohort had underlying co-morbid CVD and were more likely 
to receive statins than those without baseline CVD both before (OR= 1.62, 95% CI 
1.58-1.67) and after (OR= 1.23, 95% CI 1.17-1.28) adjusting for baseline treatment 
including statin medications, post- diagnosis. Significant disparities in statin use 
were found in gender, race/ethnicity, and age. Males were more likely than females 
to receive statins. Asians also higher statin usage compared to Caucasians, and 
those aged 65-74 were more likely use treatment compared to patients older than 
75. ConClusions: Statin treatment usage patterns vary significantly among newly 
diagnosed older adults with new onset diabetes.
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objeCtives: The availability of enhanced Medicare Part D plans with generic-only 
coverage during the coverage gap (i.e. donut hole) and the genericization of pravas-
drugs in Croatia from 2000-2013 and to identify the rate of the generic drugs 
usage as well as the average price for 1 DDD. Methods: Data on the consump-
tion have been obtained from the database IMS (International Medical Statistics) 
for Croatia. According to the World Health Organization Collaborating Centre for 
Drugs Statistics Methodology annual volumes of drugs are presented in defined 
daily doses/1000 inhabitants/day (DDD/1000), while financial expenditure data 
are presented in Euros (€ ). Results: The total usage of Agents acting on RAS 
(C09 subgroup) in constantly increasing from 58,56 DDD/1000 inh/day in 2000. to 
199,88 DDD/1000 inh/day in 2013. In 14-year period, consumption in DDD/1000 
inh/day increased 241%, while the financial expenditure in same period increased 
74% (from 28,8 mil € in 2000 to 50,3 mil € in 2013), but achieved its maximum 
in 2008 (57,7 mil € ). The consumption share of generic Agents acting on RAS 
decreased from 90% in 2000 to 56% in 2006, then constantly increasing to 68% 
in 2013. ConClusions: Drugs prescription patterns among Agents acting on 
RAS have been changing during the 14-year period in Croatia. Impact of gener-
ics decreased until 2006. Because of introduction of new original drugs, but the 
national healthare policy promoting generics resulted in their increase of share 
up to 2013. Although the generic drugs usage in C09 subgroup is relatively high, it 
should be further supported and promoted.
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objeCtives: Identify patients who were being treated for hypertension with conven-
tional release verapamil (CRV), notify the responsible of health care about cardiovas-
cular risk to which they are exposed and achieve a reduction in the number of patients 
who use it. Methods: A quasi-experimental prospective before and after study with-
out a control group was conducted in 7289 patients diagnosed with hypertension to 
be found in treatment with CRV, between October 1, 2012 and December 31, 2012 in 
8 Colombian cities from a database for dispensing medicines. Socio-demographic 
and pharmacological variables were evaluated. A total of 108 educational interven-
tions were performed for those responsible for health care, and evaluated within 
three months the proportion of suspension of the prescriptions of CRV. Multivariate 
analysis was performed using SPSS 22.0. Results: The mean age of patients was 
67.9±11.8 years (range: 26-96 years). 70.6% were men. Was obtained that discontinue 
treatment with CRV a total of 1922 patients (26.3% of users), distributed as follows: 
1160 (60.4%) were the presentation of 120 mg, while 762 (39.6%) the 80 mg. The vari-
able being treated in the city of Medellín (OR: 17.6; 95% CI: 11.949 to 25.924; p < 0.001) 
was associated statistically significant with change of CRV by another antihyperten-
sive. ConClusions: We found relative moderate adherence to recommendations 
about the proper use of CRV in hypertensive patients. Must be reinforced intervention 
programs that reduce inappropriate prescribing of potential risks to patients of insur-
ance companies and cities where the change was not achieved.
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objeCtives: This analysis provides an in-depth look at the number and types of 
drugs used by seniors, and compares drug use among seniors living in long-term 
care (LTC) facilities and those living in the community. Methods: Data from the 
National Prescription Drug Utilization Information System (NPDUIS) Database, 
housed at CIHI, as submitted by eight Provincial drug programs and one Federal 
drug program in Canada, including drug claims for approximately 70% of Canadian 
seniors. Results: In 2012, nearly two-thirds (65.9%) of seniors had claims for 5 or 
more drug classes, and more than one-quarter (27.2%) of seniors had claims for 10 
or more drug classes. The proportion of seniors age 85 and older with claims for 10 
or more drug classes (39.3%) was double that of seniors age 65 to 74 (20.0%). Six of 
the 10 drug classes most commonly used by seniors were cardiovascular-related. 
The most commonly used drug class was statins, which are used by almost half 
of seniors (46.6%). More than one-third of seniors (38.9%) had claims for a drug on 
the Beers list—a list of drugs identified as potentially inappropriate to prescribe 
to seniors. More than half of seniors living in LTC facilities were using 10 or more 
different drug classes (60.9%), more than double the proportion among seniors liv-
ing in the community (26.1%). In LTC facilities benzodiazepine use was double the 
rate, antidepressant use triple the rate and antipsychotic use nine times the rate 
among seniors living in the community. ConClusions: Findings suggest a high 
proportion of seniors, particularly those living in LTC facilities may be at risk for 
drug interactions and other adverse events due to the number of medications they 
are taking. This illustrates the importance of medication management strategies for 
seniors, and the need for communication between health care providers regarding 
seniors’ drug regimens.
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objeCtives: Generic Drug Discount Programs (GDDPs), introduced in 2006 and 
offered by the majority of retail pharmacies nationwide, offer many commonly 
used medications at low out-of-pocket prices. The objective of this study was to 
estimate the proportion of prescription claims filled using a GDDP for four com-
monly used medications. Methods: The Medical Expenditure Panel Survey annual 
prescribed medicines event file, a nationally representative sample that contains 
detailed drug information including payments made by private insurance, Medicaid/
Medicare, out-of-pocket, and other sources, was used for this study. Annual prescrip-
tion claim records, including new fills and refills of any quantity dispensed, were 
